Rauwolfia serpentina (Ophioxylon serpentinum) has been used in India for many years to treat a variety of diseases that at first thought appear to bear little similarity to one another. These include insanity, epilepsy, insomnia, hysteria, eclampsia and hypertension. On reflection, however, these various diseases could have a common denominator if they were all relieved symptomatically by a sedative or a 'relaxing' drug such as Rauwolfia. Our attention was drawn to the drug because reports of its hypotensive effects seemed to be fairly well documented; indeed, the conservative claims made for it by several authors increased rather than diminished our interest in its possible use for the treatment of hypertension.
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Bhatia, 1 in 1942, briefly reviewed the reported pharmacology of the drug and observed its clinical effects in patients with "essential" and with "renal" hypertension. He stated that the drug in the form of Serpina tablets (½ to 1 tablet at bedtime) was well tolerated and caused a moderate lowering of blood pressure.
[It was] particularly useful in relieving the nervous symptoms of high blood pressure, such as headache, tinnitus, vertigo, giddiness, insomnia, etc. Every patient remarked that he got very good sleep with this drug. In all the probability, the beneficial effect of the drug in high blood pressure is produced through its action on the nervous system. Bhatia did not comment on the bradycrotic effect of the drug.
In 1943, Gupta, Deb and Kahali, 2 in a paper on the use of the drug in the treatment of mental disorders, stressed its sedative effect and noted in a patient with epilepsy that the blood pressure decreased to 80 systolic, 56 diastolic, and the pulse to 54, "necessitating withdrawal of the drug for 2 days". Roy, 3 in 1950, also noted that the drug in manic patients slowed the pulse rate markedly.
In 1949 Vakil 4 presented a paper entitled "A Clinical Trial of Rauwolfia serpentina in Essential Hypertension." He mentioned a ten-year personal experience, and remarked on the vote by 46 of 50 Indian physicians whom he polled by mail as being in favor of this drug over all others for the treatment of hypertension. In an experimental trial of the drug alternating with placebo control, he found that 44 per cent of patients showed lowering of blood pressure by 20 or more systolic and by 10 or more diastolic Chakravarty, Rai Chaudhuri and Chaudhuri, 5 in 1951, noted in 15 cases in average decrease of 18.5 systolic and 16.4 diastolic on the tenth day of treatment. Thus, it appears from the literature that Rauwolfia serpentina is a hypotensive drug of moderate potency, that it has a sedative effect that may be related to the symptomatic relief that patients describe, and that it slows the pulse rate. The purpose of this paper is to summarize our experience, with this drug, which when given alone has duplicated essentially the results reported by others, and when given in conjunction with other hypotensive agents, notably hydrazinophthalazine, or Veratrum viride, has appeared to exert a remarkable additive, if not synergistic, hypotensive effect.
The subjects were unselected clinic or office patients with hypertension that was usually diagnosed as "essential", but in a few cases as "renal". Most of these patients had had the routine clinical and laboratory studies used in this hospital to evaluate the hypertensive state, including complete history, physical examination, urinalysis and fractional phenolsulfonephthalein test, electrocardiogram and cardiac fluoroscopy, sedation test and cold and posture test. After at least several weeks of observation, either or no medical treatment or on treatment with some other "hypotensive" drug (usually veratrum), they were started on a total of 1 to 4 (average of 2) tablets of Serpina (Manufactured by The Himalaya Drug Company, Bombay, India; obtained through the courtesy of E.R. Squibib and Sons, New York City) by mouth a day, usually in two doses (morning and night). Observations of blood pressure, pulse rate and general symptomatology were recorded at each visit (usually at weekly intervals), and, when indicated, studies such as electrocardiographic, renal or fluoroscopic were repeated. The drug was given in continuous, not in interrupted courses as in India. Veratrum viride, as "Veriloid" (Available from Riker Laboratories, Incorporated, Los Angeles, California) was usually administered in the maximum dosage tolerated by the patient (8 to 20 mg, a day in four divided doses) and hydrazinophthalazine (Available from Ciba Pharmaceutical Products, Incorporated, Summit, New Jersey) was given in gradually increasing doses (starting with 50 mg and working up to 800 mg a day in four divided doses). When Serpina alone caused the blood pressure to fall below 150 systolic, 90 diastolic, placebo were sometimes substituted but no other drug was added. Otherwise, after six to ten weeks of treatment without a reduction of pressure to below that level, one of the other two drugs was added, and if the pressure still did not return to normal within another six weeks, the third drug was added. It was found that a considerable number of patients required the combination therapy to bring the blood pressures to normal, if such a reduction could be achieved at all. However, it is not the purpose of this paper to stress the combination medical treatment of hypertension, which will be presented in detail elsewhere 6, 7 .
RESULTS

General
Serpina has now been given to over 100 patients for periods of a month to a year. On the basis of this experience it is possible to make a number of general statements:
• In an oral dosage 1 to 3 Serpina tablets a day are well tolerated for weeks and months.
• Its action is slow to appear (three to six days) and to disappear (seven to twenty one days); its chronic effects may not be fully apparent in less than six weeks.
• It produces no serious side effects.
• It causes sedation, and usually improves sleep, although occasionally it causes nightmares.
• It causes bradycardia.
• It causes nasal congestion.
• It promotes a moderate hypotension, particularly in labile patients with hypertension and tachycardia.
• It tends to promote a gain in weight.
• It occasionally changes the bowel habit to one of slightly increased frequency.
• It apparently does not cause tolerance.
• It apparently is not habit forming; administration may be easily stopped for several days to relieve any unpleasant side effects.
• It is most useful as an adjunct to more powerful hypotensive drugs. Specific Tables 1 to 4 show the responses of 59 patients followed sufficiently long and closely to allow a fair appraisal of the results. The blood-pressure and pulse-rate readings represent the averages obtained before and after treatment for the period noted. In general, the various combinations of drugs were given after trials of single drugs but not necessarily in the same sequence as shown in the tablets. It is apparent from the tablets that Serpina alone is a hypotensive agent of but modest potency and is usually incapable of reducing the blood pressure to within the normal range except when it is only moderately elevated. The drug is more effective in young, labile (neurotic), hypertensive patients with tachycardia than in those with long established, fixed hypertension with organic vascular disease (these patients usually require combination treatment).
In 13 of the 39 unselected cases in which the drug was tried alone the blood pressure could be controlled within the normal range (150 systolic, 90 diastolic, or lower). However, the average level during the control period in these 13 patients was only 173 systolic, 107 diastolic. The average blood pressure in the entire group of 39 patients before treatment was 192 systolic, 112 diastolic, and the pulse rate 82, whereas after treatment with Serpina alone the levels were 165 systolic, 95 diastolic, and 70 respectively. This compares favorably with placebo treatment in 27 patients, whose blood pressures during the control period averaged 196 systolic, 115 diastolic, but on placebos averaged 186 systolic, 111 diastolic, whereas their pulse rates averaged the same (84). On cessation of the drug, or placebo substitution, the blood pressure usually rose, but not promptly. One physician patient observed that it took four weeks after cessation of dosage for his pressure to resume pretreatment levels. In another case there was no rise in one week but a definite rise, though not to pretreatment levels, during two weeks in which the drug was withheld; after that time it was reinstituted.
In combination with the other two drugs Serpina (Tables 2, 3 , and 4) was also well tolerated and appeared to add definitely to their hypotensive effects. Thus, several patients who had been raised to the maximum dosage of Veratrum viride that they could tolerate without nausea, had a greater fall in blood pressure, occasionally associated with nausea and vomiting, when given Serpina in addition. By a slight reduction in the dosage of Veratrum viride the emetic symptoms were controlled, whereas the hypotensive response was usually maintained.
Similarly, a number of patients given hydrazinophthalazine alone with only moderate hypotensive effects had a definite further reduction of blood pressure when Serpina was added. Except for nasal congestion, Serpina appeared to reduce the side effects of hydrazinophthalazine, particularly the palpitation (tachycardia) and headache usually caused by this drug. We have been impressed with the favorable clinical effect of Serpina combined with hydrazinophthalazine even in patients with chronic and moderately severe hypertension. In 23 cases the average blood pressure was 206 systolic, 116 diastolic, before treatment with this combination and 166 systolic, 93 diastolic after treatment.
When patients failed to respond adequately on a combination of Serpina and hydrazinophthalazine or Veratrum viride, they were tired on all three drugs together (Table  4) , often with a further reduction of blood pressure. In 18 such patients the average blood pressure was 195 systolic, 117 diastolic, during the control period, and 144 systolic, 82 diastolic, during treatment with all three drugs. Thirteen of these 18 patients were controlled within the normal range; in these cases the average pressure during the control period was 189 systolic, 115 diastolic.
DISCUSSION
Serpina adds another to the rapidly increasing number of drugs, which have been tried in hypertension with favorable results in about a third to a half of the cases. Although its chemistry and pharmacology are not completely worked out, it appears to be different from many of the other agents currently being tried. It does not cause postural hypotension and therefore is not regarded as a "blocking" drug, although the nasal stuffiness and bradycardia that it produces suggest a central "sympatholytic" effect resembling that of the dihydrogenated ergot alkaloids. It has a definite sedative effect. Our initial impression was that this might be the main action, but after more than a year's experience, we have come to regard its sedative effect as coincidental. For example, I patient had one of his periodic anxiety episodes after being on the drug for a number of months, although he had no rise in blood pressure. In some cases the sedative effect may be undesirable since it is the most common reason for limiting the dosage.
Symptomatic improvement, always difficult to evaluate in hypertensive patients, was so dramatic in some cases that it should be mentioned. A sense of relaxed well-being, decrease in irritability, "improvement in personality" and relief of headache, fatigue and dyspnea were so frequently described by patients that these benefits could not be ignored. Currently, a "double blind" study 8 in which neither physician nor patient knows the content of pills being administered indicates that these symptomatic benefits are quite real, and perhaps the most easily identifiable effects of the drug.
The bradycardia produced by the drug is one of its most definite objective effects. Preliminary observations suggest that the bradycardia is not due to vagal hyperactivity since intravenous injections of atropine appears not to abolish it. Bradycardia may be particularly desirable in some hypertensive patients who habitually have tachycardia or in whom it develops during hydrazinophthalazine therapy.
Nasal congestion and, in rare cases, easy nasal bleeding suggest that the drug dilates the vasculature of the nasal mucous membranes. Patients usually attribute this symptom to a chronic cold but in some it is bothersome enough to make them try nose drops for relief. There is no adequate explanation for the gain in weight that many patients experience. There is clinical evidence that the basal metabolic rate is not changed but rather that patients are merely more relaxed and less active, sleep better and longer, and perhaps eat as much if not more on the drug than before. A few patients noted extraordinary dreams or nightmares during therapy, but these were relieved by a reduction in the dose or cessation of therapy altogether for several days.
SUMMARY AND CONCLUSIONS
The moderate hypotensive and symptomatically beneficial effects of Rauwolfia serpentina in hypertensive patients are confirmed.
A striking additive if not synergistic effect of this drug in combination with hydrazinophthalazine and with Veratrum viride is described.
The drug is well tolerated for months; it produces few side effects, and none of serious consequence. Worthy of emphasis are bradycardia, nasal congestion, sedation and tendency to gain weight.
